Saltar al contenido
Merck

NF135.C10: a new Plasmodium falciparum clone for controlled human malaria infections.

The Journal of infectious diseases (2012-11-29)
Anne C Teirlinck, Meta Roestenberg, Marga van de Vegte-Bolmer, Anja Scholzen, Moniek J L Heinrichs, Rianne Siebelink-Stoter, Wouter Graumans, Geert-Jan van Gemert, Karina Teelen, Martijn W Vos, Krystelle Nganou-Makamdop, Steffen Borrmann, Yolanda P A Rozier, Marianne A A Erkens, Adrian J F Luty, Cornelus C Hermsen, B Kim Lee Sim, Lisette van Lieshout, Stephen L Hoffman, Leo G Visser, Robert W Sauerwein
RESUMEN

We established a new field clone of Plasmodium falciparum for use in controlled human malaria infections and vaccine studies to complement the current small portfolio of P. falciparum strains, primarily based on NF54. The Cambodian clone NF135.C10 consistently produced gametocytes and generated substantial numbers of sporozoites in Anopheles mosquitoes and diverged from NF54 parasites by genetic markers. In a controlled human malaria infection trial, 3 of 5 volunteers challenged by mosquitoes infected with NF135.C10 and 4 of 5 challenged with NF54 developed parasitemia as detected with microscopy. The 2 strains induced similar clinical signs and symptoms as well as cellular immunological responses. NCT01002833.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
Proguanil hydrochloride, ≥95% (HPLC)
Número de referencia del producto (SKU)
Tamaño de envase
Disponibilidad
Precio
Cantidad